Please assess the completion status of the following clinical trial:

Trial Title: Miltefosine for Brazilian Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (untreated) visceral leishmaniasis with symptomatic disease and visualization of amastigotes in tissue samples or a positive culture.~  * Age: Group 1: 2 to 12 years; Group 2: 13 to 60 years~ * Sex: male and female patients eligible (no effort to be made to balance the study for gender)~Exclusion Criteria:~Exclusion criteria~Safety concerns:~* Thrombocyte count \<30 x 109/l;~* Leukocyte count \<1 x 109/l;~* Hemoglobin \<5 g/100 ml;~* ASAT, ALAT, AP \>3 times upper limit of normal range;~* Serum creatinine or BUN \>1.5 times upper limit of normal range;~* Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary);~* Immunodeficiency or antibody to HIV;~* Severe protein and/or caloric malnutrition (Kwashiorkor, Marasmus);~* Any non-compensated or uncontrolled condition;~* Lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months.~Lack of suitability for the trial:~* Negative bone marrow aspirate (smear);~* Any history of prior anti-leishmania therapy;~* Any condition which compromises ability to comply with the study procedures;~* Concomitant serious infection other than visceral leishmaniasis (this would include evidence of other conditions associated with splenomegaly such as schistosomiasis or malaria).~Administrative reasons:~* Lack of ability or willingness to give informed consent (patient and/or parent / legal representative);~* Anticipated non-availability for study visits/procedures.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).